ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ikena Cuts Back As BMS Unravels Partner
ScripTaiwan may be dominating global headlines this week over the reactions to US House Speaker Nancy Pelosi’s controversial visit, but for the global pharma industry already operating there, it was issues
Pink SheetAn expert panel is assessing whether two more candidate COVID-19 vaccines, from Arcturus and Codagenix, should be added to the global Solidarity Trial Vaccines (STV) initiative, which has been set up
ScripSeres Therapeutics’ SER-109 Seres Therapeutics, Inc. is expected to file for approval of SER-109 in late 2021 or early 2022, paving the way for it to become the first microbiome therapeutic approved